Diagnosis and management of polycystic ovary syndrome

Journal of Clinical Outcomes Management

Volumn 12, Issue 4, 2005, Pages 218-226

  Raja Khan, Nazia ^a   Legro, Richard S ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIANDROGEN; CLOMIFENE CITRATE; CYPROTERONE ACETATE; EFLORNITHINE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUTAMIDE; FOLLITROPIN; GONADORELIN; GONADOTROPIN; INSULIN; INSULIN RECEPTOR; INSULIN SENSITIZING AGENT; LUTEINIZING HORMONE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE; TESTOSTERONE; TROGLITAZONE;

ACNE; ADJUVANT THERAPY; ANDROGEN BLOOD LEVEL; ANOVULATION; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIARRHEA; DIET; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG TOLERABILITY; EARLY DIAGNOSIS; EDEMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EXERCISE; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HIGH RISK POPULATION; HIRSUTISM; HUMAN; INFERTILITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LABORATORY TEST; LIFESTYLE; LIVER TOXICITY; LONG TERM CARE; LOW CALORY DIET; LOW LEVEL LASER THERAPY; LUTEINIZING HORMONE BLOOD LEVEL; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOPHYSIOLOGY; PREGNANCY; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; TERATOGENICITY; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 18744401624     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected Black and White women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
2. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
3. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003;24:302-12.
4. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992:377-84.
5. Chang PL, Lindheim SR, Lowre C, et al. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. J Clin Endocrinol Metab 2000;85: 995-1000.
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
7. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505-14.
8. Rebar R, Judd HL, Yen SS, et al. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976;57:1320-9.
9. Morales AJ, Laughlin GA, Butzow T, et al. Insulin, somatotropic, and lutenizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996;81:2854-64.
10. Ehrmann DA, Kasza K, Azziz R, et al. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2005;90:66-71.
11. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists: number 41, December 2002. Obstet Gynecol 2002;100:1389-402.
12. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-13.
13. Ibanez L, Valls C, Miro E, et al. Early menarche and subchnical ovarian hyperandrogenisin in girls with reduced adult height after low birth weight. J Ped Endocrinol Metab 2002; 15:431-3.
14. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Hormone Res 2001;56:295-308.
15. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-11.
16. Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994;61:598-604.
17. Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebocontrolled trial. J Clin Endocrinol Metab 2002;87:569-74.
18. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.
19. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-3.
20. Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 1990;42:611-9.
21. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-4.
22. Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-5.
23. Legro RS, Bentley-Lewis R, Driscoll D, et al. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002;87:2128-33.
24. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features endocrine and metabolic profiles and hisulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46.
25. Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002;77:209-15.
26. George SS, George K, Irwin C, et al. Sequential treatment of metformin and clomiphene citrate in domiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 2003;18:299-304.
27. Clinical practice recommendations 2005. Diabetes Care 2005; 28 Suppl 1:S1-79.
28. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002;17:2858-64.
29. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524-9.
30. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24-8.
31. Winters SJ, Talbott E, Guzick DS, et al. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:724-9.
32. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma [published erratum appears in Lancet 2003;362:1082]. Lancet 2003;361:1810-2.
33. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia. in polycystic ovary syndrome. Obstet Gynecol 2001;98:325-31.
34. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013-7.
35. Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562-8.
36. Talbott EC, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-21.
37. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-5.
38. Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study [published erratum appears in J Clin Endocrinol Metab 2004;89: 5621]. J Clin Endocrinol Metab 2004;89:3696-701.
39. Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus; in polycystic ovarian syndrome. Hum Reprod 2001;16:1995-8.
40. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
41. Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.
42. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.
43. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:4649-54.
44. Paradisi G, Steinberg HO, Shepard MK, et al. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:576-80.
45. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-32.
46. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902.